Brutieridin–Melitidin Mixture Cancer Research Results

BMF, Brutieridin–Melitidin Mixture: Click to Expand ⟱
Features:

Brutieridin–Melitidin Mixture (BMF) — a defined combination of two naturally occurring 3-hydroxy-3-methylglutaryl (HMG)-substituted flavanone glycosides derived from bergamot (Citrus bergamia). The experimentally studied mixture contains approximately 70% brutieridin and 30% melitidin, described as a roughly 2:1 combination. Brutieridin is a hesperetin-derived HMG-flavanone glycoside, whereas melitidin is a naringenin-derived HMG-flavanone glycoside. BMF is classified as a plant-derived polyphenolic combination with experimental anticancer stem-cell and metabolic-modulating activities. It is distinct from whole bergamot juice, bergamot essential oil and the broader bergamot polyphenolic fraction (BPF). Most direct anticancer evidence comes from a preclinical breast cancer study using this defined mixture.

Primary mechanisms (ranked):

  1. Cancer stem-cell (CSC) suppression: BMF reduces aldehyde dehydrogenase (ALDH) activity and mammosphere formation, inhibiting functional characteristics associated with breast cancer stemness.
  2. Mevalonate pathway and HMG-CoA reductase (HMGCR) axis modulation: BMF exhibits statin-like effects associated with suppression of cancer-cell growth and stemness. Direct catalytic inhibition of HMGCR remains uncertain because subsequent experiments with the isolated constituent flavonoids did not demonstrate significant inhibition at the tested concentrations.
  3. Rho-GDI-associated signalling modulation: BMF alters Rho-GDI-associated pathways and suppresses CSC-related STAT1/STAT3, Notch and Wnt/β-catenin signalling.
  4. Mitochondrial oxidative phosphorylation (OXPHOS) inhibition: BMF suppresses mitochondrial respiration in breast cancer cells, potentially limiting energy availability for CSC maintenance and proliferation.
  5. Fatty-acid oxidation (FAO) inhibition: BMF reduces mitochondrial fatty-acid utilization, potentially restricting metabolic flexibility in cancer cells.
  6. Suppression of cancer-cell proliferation: BMF reduces growth of MCF7 breast cancer cells in prolonged high-concentration experiments. Its effects in other tumor types remain insufficiently established.

Bioavailability / PK relevance: Human pharmacokinetic studies of the defined BMF mixture are lacking. In a pilot study involving oral bergamot juice, intact HMG-substituted flavanones, including brutieridin and melitidin, were not detected in plasma or urine, whereas glucuronidated and sulfated metabolites of related flavanones were measurable. Oral absorption, metabolism, tissue distribution and elimination of purified BMF have not been adequately characterized. These findings indicate substantial uncertainty about systemic exposure to unchanged BMF after oral administration. Results from whole bergamot preparations should not be considered equivalent to the pharmacokinetics of purified BMF.

In-vitro vs systemic exposure relevance: The principal anticancer investigation tested BMF at nominal concentrations of 100 µM and 1 mM during prolonged cell exposure, including 72–120-hour proliferation experiments. These concentrations substantially exceed demonstrated circulating exposure to intact HMG-flavanones following oral bergamot juice consumption. Because BMF contains two compounds with different molecular weights, reported mixture molarity should be interpreted with attention to the experimental formulation. No validated human oral dose has been demonstrated to achieve the anticancer concentrations used in vitro.

Clinical evidence status: Preclinical only for cancer. BMF has demonstrated inhibition of breast cancer stem-cell phenotypes and cancer-associated metabolic pathways in laboratory models, but there is no established evidence of anticancer efficacy in humans. No clinical cancer treatment, survival benefit, radiosensitization or chemotherapy enhancement has been validated for the defined mixture. Human bergamot studies investigating cholesterol and metabolic outcomes involve different preparations and cannot establish BMF-specific clinical efficacy. BMF is not an approved anticancer therapy. Chronic safety, drug interactions, systemic dose limits and tolerability of purified BMF remain inadequately characterized.

BMF Cancer Mechanisms

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 Cancer stem cells and ALDH ↓ ALDH activity; ↓ mammosphere formation Not established G Reduced CSC activity and self-renewal phenotype Core BMF effect demonstrated in MCF7 breast cancer cells. Mammosphere suppression supports reduced stemness, but clinical recurrence prevention has not been demonstrated.
2 Mevalonate and HMGCR axis ↓ (context-dependent) Not established G Statin-like metabolic and proliferative suppression Fiorillo et al. reported HMGCR-associated activity for BMF. A later direct enzyme study found no significant inhibition by isolated brutieridin or melitidin at 10 µM. Direct HMGCR inhibition by BMF therefore remains mechanistically uncertain.
3 STAT1 and STAT3 signalling ↓ Not established G Suppression of cancer stemness signalling BMF inhibited STAT1/STAT3-associated CSC signalling. This is a preclinical pathway observation rather than proof of direct STAT protein binding.
4 Notch signalling ↓ Not established G Reduced stem-cell maintenance signalling Reported with BMF treatment in the MCF7 CSC model. Effects in other tumor types have not been established.
5 Wnt and β-catenin signalling ↓ Not established G Reduced stemness-associated transcriptional signalling BMF suppressed Wnt/β-catenin-associated CSC signalling. Direct molecular targets within the pathway remain uncertain.
6 Rho-GDI signalling Modulated (context-dependent) Not established G Altered signalling associated with CSC regulation Identified as an important BMF-associated signalling mechanism. A uniform activation or inhibition direction should not be assigned without specifying the individual Rho-GDI pathway component and measured endpoint.
7 Mitochondrial oxidative phosphorylation ↓ OXPHOS Not established G Reduced mitochondrial energy production Directly reported for BMF-treated breast cancer cells. Normal fibroblast tolerability was comparatively favorable, but complete selectivity of mitochondrial effects has not been established.
8 Fatty-acid oxidation ↓ FAO Not established G Reduced mitochondrial substrate utilization BMF suppressed FAO in the cancer model. This may contribute to impaired metabolic flexibility and CSC maintenance.
9 Cancer-cell proliferation ↓ (dose-dependent) Lower cytotoxicity in tested fibroblasts G Reduced tumor-cell growth MCF7 and HMGCR-overexpressing MCF7 models were evaluated with BMF at nominal concentrations of 100 µM and 1 mM for 72–120 hours. These concentrations are not validated as achievable human tumor exposures.
10 Normal-cell toxicity ↓ cancer-cell viability Relatively preserved fibroblast viability G Possible experimental therapeutic selectivity BMF displayed a more favorable toxicity profile in the tested normal fibroblasts than comparator statins. This does not establish systemic safety or absence of toxicity in other normal tissues.
11 Clinical Translation Constraint ↔ ↔ G Uncertain oral exposure and clinical efficacy Defined BMF human PK studies and cancer trials are lacking. Intact HMG-flavanones were not detectable following ordinary bergamot juice ingestion in the available pilot study. High experimental concentrations, metabolism, tumor heterogeneity and formulation requirements limit clinical interpretation.

P: 0–30 min R: 30 min–3 hr G: >3 hr
Scientific Papers found: Click to Expand⟱
8703- BMF,    Bergamot natural products eradicate cancer stem cells (CSCs) by targeting mevalonate, Rho-GDI-signalling and mitochondrial metabolism
- in-vitro, Var, NA
HMGCR↓, CSCs↓, ALDH↓, STAT3↓, NOTCH↓, Wnt↓, β-catenin/ZEB1↓, OXPHOS↓, FAO↓, selectivity↑, Ingr↝, HMG-CoA↓, Rho↓, p27/CDKN1B↑, mitResp↓, compI↓, compII↓, compIV↓, compV↓, OCR↓, ATP↓,
8704- BMF,    Defining the Cholesterol Lowering Mechanism of Bergamot (Citrus bergamia) Extract in HepG2 and Caco-2 Cells
- in-vitro, Liver, HepG2 - in-vitro, Colon, Caco-2
TC↓, HMGCR↓,

Showing Research Papers: 1 to 2 of 2

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 2

Pathway results for Effect on Cancer / Diseased Cells:


Mitochondria & Bioenergetics(tgid=3) ⓘ

compI↓, 1,   compII↓, 1,   compIV↓, 1,   compV↓, 1,   mitResp↓, 1,   OCR↓, 1,   OXPHOS↓, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

ATP↓, 1,   FAO↓, 1,   HMG-CoA↓, 1,  

Kinase & Signal Transduction(tgid=6) ⓘ

STAT3↓, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

p27/CDKN1B↑, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

ALDH↓, 1,   CSCs↓, 1,   HMGCR↓, 2,   NOTCH↓, 1,   Wnt↓, 1,  

Migration(tgid=13) ⓘ

Rho↓, 1,   β-catenin/ZEB1↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

selectivity↑, 1,  

Clinical Biomarkers(tgid=22) ⓘ

TC↓, 1,  

Ingredients & Constituents(tgid=25) ⓘ

Ingr↝, 1,  
Total Targets: 22

Pathway results for Effect on Normal Cells:


Total Targets: 0

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:269  Target#:%  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page